



**~~THIS LETTER CONTAINS PROPRIETARY AND EXPORT CONTROLLED INFORMATION
IN ACCORDANCE WITH 10 CFR 2.390~~**

June 10, 2022

2022-SMT-0065
10 CFR 50.30

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
Washington, DC 20555

References: (1) SHINE Medical Technologies, LLC letter to the NRC, "SHINE Medical Technologies, LLC Application for an Operating License," dated July 17, 2019 (ML19211C143)

SHINE Technologies, LLC Application for an Operating License Supplement No. 23

Pursuant to 10 CFR Part 50.30, SHINE Technologies, LLC (SHINE) submitted an application for an operating license for a medical isotope production facility to be located in Janesville, Wisconsin (Reference 1). SHINE has determined that a supplement to the operating license application is necessary to address open technical items discussed with the NRC staff during regulatory audits and to address facility design changes.

This submittal contains information which SHINE requests to be withheld from public disclosure, including proprietary information in accordance with 10 CFR 2.390(a)(4) and export controlled information (ECI) in accordance with 10 CFR 2.390(a)(3).

Enclosure 1 provides the non-public version of the SHINE Final Safety Analysis Report (FSAR) Change Summary, including a mark-up of affected FSAR pages not previously submitted. Enclosure 1 contains proprietary information, a subset of which has been determined to be ECI. SHINE requests that the NRC withhold Enclosure 1 from public disclosure under 10 CFR 2.390.

Enclosure 2 provides the public version of the SHINE FSAR Change Summary.

Enclosure 3 provides an affidavit supporting the proprietary treatment of the SHINE proprietary information contained in Enclosure 1, pursuant to 10 CFR 2.390. SHINE requests that the NRC withhold Enclosure 1 from public disclosure under 10 CFR 2.390. Upon removal of Enclosure 1, this letter is uncontrolled.

If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.

Document Control Desk
Page 2

I declare under the penalty of perjury that the foregoing is true and correct.
Executed on June 10, 2022.

Very truly yours,

DocuSigned by:

F52DB96989224FF...

James Costedio
Vice President of Regulatory Affairs and Quality
SHINE Technologies, LLC
Docket No. 50-608

Enclosures

cc: Project Manager, USNRC
SHINE General Counsel
Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health
(w/o Enclosure 1)